bioAffinity Technologies, Inc. (BIAF)
(Delayed Data from NSDQ)
$0.29 USD
-0.02 (-7.38%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $0.29 0.00 (-1.23%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIAF 0.29 -0.02(-7.38%)
Will BIAF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIAF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIAF
The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies
Top Research Reports for Meta Platforms, ServiceNow & Booking
BIAF: What are Zacks experts saying now?
Zacks Private Portfolio Services
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies
Top Stock Reports for Alphabet, Berkshire Hathaway & Visa
Other News for BIAF
BIAF Gains Canadian Patent for Innovative Lung Disease Detection Method | BIAF Stock News
BioAffinity Technologies awarded new Canadian patent for CyPath Lung